BioSpace News Archive

Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Michael F. MacLean, chief financial officer of Avidity Biosciences, has joined the company’s board of directors.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced that restoration of retinal tissue was observed in two additional patients enrolled in the Company’s Phase 1/2a study of its lead product candidate, OpRegen.

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the election of Derrell D. Porter, M.D., to its board of directors and his appointment to the Audit Committee, effective as of May 27, 2021, the date of Passage Bio’s Annual Meeting of Stockholders.

On May 28, 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announces considerable investments in strengthening its Vietnam based production operations.

Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN prevention for the first time in 30 years

EnginZyme, leading the change towards sustainable production of chemicals, announces the appointment of new members to the company’s board of directors, marking the company scaling up and strengthening the position in the synbio industry.

CTI BioPharma Corp. announced that the U.S. Food and Drug Administration has accepted its New Drug Application for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, with the NDA being granted Priority Review.

APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy